Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/nrc3239 http://scihub22266oqcxt.onion/10.1038/nrc3239 C4856023!4856023 !22437870     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\22437870 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Nat+Rev+Cancer 2012 ; 12 (4 ): 252-64 Nephropedia Template TP {{tp|p=22437870 |t=2012. The blockade of immune checkpoints in cancer immunotherapy |pdf=|usr=}}{{22437870 }} gab.com Text The blockade of immune checkpoints in cancer immunotherapy JO: Nat Rev Cancer http://www.kidney.de/pget.php?&tw=1&pmid=22437870 #FOAvip Among the most promising approaches to activating therapeutic antitumour immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. It is now clear that tumours co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumour antigens. Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval. Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses. Twit Text FOAVip The blockade of immune checkpoints in cancer immunotherapy ????Nat Rev Cancer http://www.kidney.de/pget.php?&tw=1&pmid=22437870 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=22437870 #FOAvip English Wikipedia <ref>{{Cite pmid|22437870 }}</ref> The blockade of immune checkpoints in cancer immunotherapy #MMPMID22437870 Pardoll DM Nat Rev Cancer 2012[Mar]; 12 (4 ): 252-64 PMID22437870 show ga Among the most promising approaches to activating therapeutic antitumour immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. It is now clear that tumours co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumour antigens. Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval. Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses. |Animals [MESH] |Antigens, Neoplasm/immunology/metabolism [MESH] |CTLA-4 Antigen/physiology [MESH] |Cancer Vaccines/therapeutic use [MESH] |Clinical Trials as Topic [MESH] |Humans [MESH] |Immunotherapy [MESH] |Molecular Targeted Therapy [MESH] |Neoplasms/immunology/metabolism/*therapy [MESH] |Programmed Cell Death 1 Receptor/physiology [MESH]The blockade of immune checkpoints in cancer immunotherapy (epmc).pdf DeepDyve Pubget Overpricing